Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A retrospective, single-center study examining patients with early stage TNBC who received pembrolizumab combined with neoadjuvant carboplatin/paclitaxel followed by doxorubicin/cyclophosphamide

Next Previous
Search
Trial Profile

A retrospective, single-center study examining patients with early stage TNBC who received pembrolizumab combined with neoadjuvant carboplatin/paclitaxel followed by doxorubicin/cyclophosphamide

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; Carboplatin; Cyclophosphamide; Doxorubicin; Paclitaxel
  • Indications Early breast cancer; Triple negative breast cancer
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 09 Feb 2023 New trial record
    • 10 Dec 2022 Results presented at the 45th Annual San Antonio Breast Cancer Symposium

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top